Hoon-Gu Kim
Overview
Explore the profile of Hoon-Gu Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Go S, Kang M, Kim H
J Hosp Palliat Care
. 2025 Mar;
28(1):10-17.
PMID: 40070849
Sarcopenia, characterized by progressive loss of skeletal muscle mass and strength, is a prevalent but often overlooked condition in patients with cancer who are terminally ill. It contributes to functional...
2.
Go S, Choi B, Park M, Park S, Kang M, Kim H, et al.
BMC Cancer
. 2023 Nov;
23(1):1071.
PMID: 37932700
Background: Although the prognostic value of the Controlling Nutritional Status (CONUT) score in diffuse large B-cell lymphoma (DLBCL) has been reported in several previous studies, its clinical relevance for the...
3.
Go S, Park S, Kang M, Kim H, Kang J, Kim J, et al.
Cancer Biomark
. 2022 Sep;
35(2):217-225.
PMID: 36120771
Background: Endothelial activation and insult may contribute to the aggressive clinical course of small-cell lung cancer (SCLC); however, no predictive biomarker for this pathogenesis has been identified. Objective: To evaluate...
4.
Ahn S, Son S, Lee G, Kim I, Cheong J, Lee W, et al.
Blood Res
. 2022 Jun;
57(2):144-151.
PMID: 35678158
Background: Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)....
5.
Kim K, Lee J, Lee M, Kim H, Do Y, Park Y, et al.
Cancer Res Treat
. 2022 Apr;
55(1):304-313.
PMID: 35381164
Purpose: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin's lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning...
6.
Park H, Kang S, Kim I, Kim S, Kim H, Shin D, et al.
Leuk Res
. 2022 Feb;
114:106791.
PMID: 35101736
Genetic differences may be associated with the response to tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia (CML). In this study, we identified genetic alterations between rapid and...
7.
Go S, Park M, Park S, Kang M, Kim H, Kang J, et al.
J Cachexia Sarcopenia Muscle
. 2021 Oct;
12(6):2211-2219.
PMID: 34676685
Background: Cancer cachexia is known to adversely affect the clinical course in patients with malignant lymphoma. The cachexia index (CXI) is a potential biomarker of cancer cachexia, and its implications...
8.
Park H, Kim I, Kim H, Shin D, Lee S, Kwon O, et al.
Leuk Res
. 2021 Oct;
111:106728.
PMID: 34673444
Ultra-deep sequencing detects low-frequency genetic mutations with high sensitivity. We used this approach to prospectively examine mutations in the BCR/ABL1 tyrosine kinase from patients with newly diagnosed, chronic-phase chronic myeloid...
9.
Park K, Kim J, Kim J, Kim Y, Kim H, Cho E, et al.
BMC Cancer
. 2021 Jul;
21(1):802.
PMID: 34253172
Background: Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its 'real-world' safety and efficacy....
10.
Hong M, Heo S, Lee Y, Kim H, Park K, Kim H, et al.
Cancer
. 2020 Aug;
126(20):4521-4531.
PMID: 32749686
Background: The objective of the current study was to investigate the clinical activity of, safety of, and predictive biomarkers for afatinib, an irreversible pan-ErbB kinase inhibitor, in patients with recurrent...